Evogene (NASDAQ:EVGN – Get Free Report) and Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.
Institutional & Insider Ownership
10.4% of Evogene shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 7.4% of Evogene shares are owned by company insiders. Comparatively, 17.6% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Evogene and Madrigal Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evogene | $3.85 million | 1.10 | -$8.48 million | ($0.91) | -0.53 |
| Madrigal Pharmaceuticals | $958.40 million | 12.84 | -$288.28 million | ($12.89) | -41.32 |
Evogene has higher earnings, but lower revenue than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Evogene, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Evogene and Madrigal Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evogene | 1 | 0 | 0 | 0 | 1.00 |
| Madrigal Pharmaceuticals | 1 | 2 | 15 | 0 | 2.78 |
Madrigal Pharmaceuticals has a consensus target price of $699.64, indicating a potential upside of 31.38%. Given Madrigal Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Madrigal Pharmaceuticals is more favorable than Evogene.
Profitability
This table compares Evogene and Madrigal Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evogene | -694.18% | -156.53% | -86.80% |
| Madrigal Pharmaceuticals | -25.32% | -56.65% | -25.53% |
Risk & Volatility
Evogene has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.98, meaning that its share price is 198% less volatile than the S&P 500.
Summary
Madrigal Pharmaceuticals beats Evogene on 10 of the 14 factors compared between the two stocks.
About Evogene
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.
